...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: AGM

One thing to add to Bear's notes.  There wasn't much in the way of Q&A but I did ask Don if he could differentiate for us between Zen-3694 and Gilead's Gs-5892.  He said he couldn't go into too much detail for proprietary reasons but that Zenith's product has a better toxicology profile.

Share
New Message
Please login to post a reply